

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S56–S71
S65
Disclosure of interest
The author has not supplied his declaration
of competing interest.
http://dx.doi.org/10.1016/j.eurpsy.2016.01.962Schizophrenia research: The necessary link
between psychopathology and clinical
neuroscience
W29
From Griesinger to DSM-V: Do we
need the diagnosis of schizophrenia?
A. Erfurth
1 ,∗
, G. Sachs
21
Otto-Wagner-Spital, 6th Psychiatric Department, Vienna, Austria
2
Medical University of Vienna, Department of Psychiatry and
Psychotherapy, Vienna, Austria
∗
Corresponding author.
The dichotomy between “dementia praecox” and “manic-
depressive insanity” by Emil Kraepelin is one of the milestones of
nosology in psychiatry
[1] .This dichotomy reflects the necessity – particularly in the absence
of effective treatment in Kraepelin’s time – to differentiate (and to
predict) the functional outcome of individual patients. Since Krae-
pelin’s original division particularly the influence of Kurt Schneider
has led to a full acknowledgment of the dichotomy in both ICD and
DSM.
While this division has proven to be clinically useful, alternatives
have been proposed covering a large spectrum from the idea of uni-
tary psychosis as inWilhelmGriesinger and Klaus Conrad to further
subdivisions as in Karl Leonhard. Recent research in neuroscience
suggests the presence of an overlap between schizophrenia and
other psychiatric disorders
[2–4] .Disclosure of interest
The author has not supplied his declaration
of competing interest.
References
[1] Kraepelin E. Psychiatrie. 6th edition Leipzig: J.A. Barth; 1899.
[2] Smoller JW, et al. Lancet 2013;381:1371–9.
[3] Lee SH, et al. Nat Genet 2013;45:984–94.
[4] Padmanabhan JL, et al. Schizophr Bull 2015;41(1):154–62.
http://dx.doi.org/10.1016/j.eurpsy.2016.01.963W30
Role of psychopathology in
elucidating the underlying neural
mechanisms
F. Oyebode
Birmingham, United Kingdom
Introduction
Psychopathology is the systematic study of abnor-
mal subjective experience and behaviour and it aims to give precise
description, categorisation and definition of abnormal subjective
experiences.
Aim
I aim to demonstrate that the most appropriate approach to
elucidating the biological origins of psychiatric disorders is firstly to
identify elementary abnormal phenomena and then to relate these
to their underlying neural mechanisms. I will exemplify this by
drawing attention to studies of Delusional Misidentification Syn-
dromes (DSM).
Results
I will show that there are impairments in face recogni-
tion memory in individuals with DSM without impairments in the
recognition of emotion and that there are abnormalities of right
hemisphere function and of the autonomic recognition pathways
that determine sense of familiarity.
Conclusions
Basic psychopathological phenomena are more
likely to throw light on the basic neuralmechanisms that are impor-
tant in psychiatric disorders than studying disease level categories.
Disclosure of interest
The author has not supplied his declaration
of competing interest.
http://dx.doi.org/10.1016/j.eurpsy.2016.01.964W31
The role of cognition in the
psychopathology of schizophrenia:
Assessment and treatment options
G. Sachs
1 ,∗
, I. Lasser
1 , B. Winklbaur
1 , E. Maihofer
2 , A. Erfurth
21
Medical University of Vienna, Department of Psychiatry and
Psychotherapy, Vienna, Austria
2
Otto Wagner Spital, Vienna, Austria
∗
Corresponding author.
Cognitive dysfunction is a characteristic feature of patients
with schizophrenia. Traditionally, the main distinction between
“dementia praecox” and “manic-depressive insanity” was in fact
the cognitive outcome during the course of the disease
[1] .For the assessment of cognitive dysfunction both large, detailed
instruments
[2] and brief screening scales for quick and multiple
use
[3,4] are available.
Recently, the role of social cognition has been thoroughly examined
showing differential effects
[5] .Treatment of cognitive dysfunction in schizophrenia comprises
adherence to a therapy with atypical antipsychotics as well as spe-
cific treatment programs for cognitive
[6] and social cognitive
[7,8]dysfunction.
Disclosure of interest
The authors have not supplied their decla-
ration of competing interest.
References
[1] Kraepelin E. Psychiatrie. 6th edition Leipzig: J.A. Barth; 1899.
[2] Green MF, et al. Am J Psychiatry 2014;171(11):1151–4.
[3] Sachs G, et al. Eur Psychiatry 2011;26(2):74–7.
[4] Cuesta MJ, et al. Schizophr Res 2011;130(1–3):137–42.
[5] Green MF, et al. Nat Rev Neurosci 2015;16(10):620–31.
[6] Wykes T, et al. Am J Psychiatry 2011;168(5):472–85.
[7] Kurtz MM, et al. Clin Psychol Rev 2015 [Epub ahead of print].
[8] Sachs G, et al. Schizophr Res 2012;138(2–3):262–7.
http://dx.doi.org/10.1016/j.eurpsy.2016.01.965Shaping the future of healthcare through
innovation and technology
W32
New research in outcome
management using apps and DSM-5
measures. Preliminary results
V.J.A. Buwalda
Vrije Universiteit/Victas addiction Center, Psychiatry, Amsterdam,
Netherlands
The presentation is about the use of outcome measurements in
combination of a newly developed app that enables psychiatrists
and patients track the progress of their treatment process and
adjust it if needed in an shared decision fashion.
In 2013 the fifth edition of the Diagnostic and Statistical Manual
of Mental Disorders was introduced. Around the same time there
was the start of a paradigm shift in healthcare which increased the
focus on patient involvement in individual health care decision-
making and onmeasuring and improving outcomes of care (Sederer